Cost-effectiveness analysis of colonoscopy and fecal immunochemical testing for colorectal cancer screening in China

被引：13

作者：

Ren, Yinan ^{[1
,2
]}

Zhao, Mingye ^{[1
,2
]}

Zhou, Dachuang ^{[1
,2
]}

Xing, Qian ^{[1
,2
]}

Gong, Fangfang ^{[3
]}

Tang, Wenxi ^{[1
,2
]}

机构：

[1] China Pharmaceut Univ, Sch Int Pharmaceut Business, Nanjing, Peoples R China

[2] China Pharmaceut Univ, Ctr Pharmacoecon & Outcomes Res, Nanjing, Peoples R China

[3] Shenzhen Univ, Dept Hosp Grp Off, Shenzhen Luohu Hosp Grp Luohu Peoples Hosp, Affiliated Hosp 3, Shenzhen, Peoples R China

来源：

FRONTIERS IN PUBLIC HEALTH | 2022年 / 10卷

基金：

中国国家自然科学基金;

关键词：

colorectal cancer; screening; electronic colonoscopy; fecal immunochemical testing; economic evaluation; COLON-CANCER; RISK; GUIDELINES; MANAGEMENT; DIAGNOSIS; DISEASE; ADENOMA; POLYPS; TRIAL;

D O I：

10.3389/fpubh.2022.952378

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

ObjectiveThis study aimed to evaluate the cost-effectiveness of the colorectal cancer screening in China, and that when the screening was implemented in a specific region. MethodsA 13-state Markov model was established to compare four screening protocols, including annual fecal immunochemical testing (FIT1), biennial fecal immunochemical testing (FIT2), electronic colonoscopy every 10 years (e-CSPY10), and electronic colonoscopy every 5 years (e-CSPY5), with no screening from the perspective of Chinese healthcare system. The model simulated the health states of a cohort of 100,000 average-risk individuals aging from 50 to 75. Additionally, scenarios including the implementation in a specific region, starting from 40, and incompletely successful treatment of cancer were also analyzed. ResultsAnnual and biennial FIT could save 8.13USD (US Dollar) and 44.96USD per person, and increase 0.0705QALYs (Quality-Adjusted Life Years) and 0.2341 QALYs compared with no screening, respectively. Annual FIT could decrease costs by 36.81USD per person and increase 0.1637 QALYs in comparison to biennial FIT. The results showed that both annual and biennial FIT for screening were dominant over no screening, and annual FIT was dominant over biennial FIT. The ICER (Incremental Cost-Effectiveness Ratio) for e-CSPY10 were 1183.51USD/QALY and 536.66USD/QALY compared with FIT1 and FIT2. The ICER for e-CSPY5 were 1158.16USD/QALY and 770.85USD/QALY compared with FIT1 and FIT2. And the ICER for e-CSPY5 relative to e-CSPY10 was 358.71USD/QALY. All the ICER values were lower than the economic threshold of 2021 Chinese GDP (Gross Domestic Product) per capita in 2021(12554.42USD). ConclusionsIt is worthwhile to popularize CRC screening in mainland China, as FIT always saving costs and colonoscopy is cost-effective. Regions with high income can take electronic colonoscopy every 10 years, or even every 5 years into consideration when determining the specific strategies.

引用

页数：14

共 66 条

[1] Fap2 Mediates Fusobacterium nucleatum Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc [J].

Abed, Jawad ;

Emgard, Johanna E. M. ;

Zamir, Gideon ;

Faroja, Mouhammad ;

Almogy, Gideon ;

Grenov, Amalie ;

Sol, Asaf ;

Naor, Ronit ;

Pikarsky, Eli ;

Atlan, Karine A. ;

Mellul, Anna ;

Chaushu, Stella ;

Manson, Abigail L. ;

Earl, Ashlee M. ;

Ou, Nora ;

Brennan, Caitlin A. ;

Garrett, Wendy S. ;

Bachrach, Gilad .

CELL HOST & MICROBE, 2016, 20 (02) :215-225

[2]

ACKROYD FW, 1985, ANNU REV MED, V36, P619

[3] Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Argiles, G. ;

Tabernero, J. ;

Labianca, R. ;

Hochhauser, D. ;

Salazar, R. ;

Iveson, T. ;

Laurent-Puig, P. ;

Quirke, P. ;

Yoshino, T. ;

Taieb, J. ;

Martinelli, E. ;

Arnold, D. .

ANNALS OF ONCOLOGY, 2020, 31 (10) :1291-1305

[4] Cost-effectiveness of high-sensitivity faecal immunochemical test and colonoscopy screening for colorectal cancer [J].

Aronsson, M. ;

Carlsson, P. ;

Levin, L. -A. ;

Hager, J. ;

Hultcrantz, R. .

BRITISH JOURNAL OF SURGERY, 2017, 104 (08) :1078-1086

[5] Histologic Factors Associated With Need for Surgery in Patients With Pedunculated T1 Colorectal Carcinomas [J].

Backes, Yara ;

Elias, Sjoerd G. ;

Groen, John N. ;

Schwartz, Matthijs P. ;

Wolfhagen, Frank H. J. ;

Geesing, Joost M. J. ;

ter Borg, Frank ;

van Bergeijk, Jeroen ;

Spanier, Bernhard W. M. ;

Tot, Wouter H. de Vos ;

Cappel, Nederveen ;

Kessels, Koen ;

Seldenrijk, Cornelis A. ;

Raicu, Mihaela G. ;

Drillenburg, Paul ;

Milne, Anya N. ;

Kerkhof, Marjon ;

Seerden, Tom C. J. ;

Siersema, Peter D. ;

Vleggaar, Frank P. ;

Offerhaus, G. Johan A. ;

Lacle, Miangela M. ;

Moons, Leon M. G. .

GASTROENTEROLOGY, 2018, 154 (06) :1647-1659

[6] Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies [J].

Brenner, Hermann ;

Stock, Christian ;

Hoffmeister, Michael .

BMJ-BRITISH MEDICAL JOURNAL, 2014, 348

[7] Malignant colorectal polyps [J].

Bujanda, Luis ;

Cosme, Angel ;

Gil, Ines ;

Arenas-Mirave, Juan I. .

WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (25) :3103-3111

[8] Cost-Effectiveness between Double and Single Fecal Immunochemical Test(s) in a Mass Colorectal Cancer Screening [J].

Cai, Shan-Rong ;

Zhu, Hong-Hong ;

Huang, Yan-Qin ;

Li, Qi-Long ;

Ma, Xin-Yuan ;

Zhang, Su-Zhan ;

Zheng, Shu .

BIOMED RESEARCH INTERNATIONAL, 2016, 2016

[9] Pathophysiology, clinical presentation, and management of colon cancer [J].

Cappell, Mitchell S. .

GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2008, 37 (01) :1-+

[10]

Chen L, 2016, CHINESE J GASTROENTE, V21, P528, DOI 10.3969/j.issn.1008-7125.2016.09.004

← 1 2 3 4 5 6 7 →